Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Onconova Therapeutic
(NQ:
ONTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Onconova Therapeutic
< Previous
1
2
3
4
5
6
Next >
Traws Pharma Announces New Employee Inducement Grants
April 02, 2024
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
April 02, 2024
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
March 08, 2024
Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics's Earnings: A Preview
November 13, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 15, 2024
Via
Benzinga
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
December 12, 2023
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.
Via
Benzinga
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
December 12, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
December 11, 2023
Via
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 11, 2023
Via
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
December 11, 2023
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 11, 2023
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
December 08, 2023
Via
Benzinga
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
December 08, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 28, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
November 14, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
November 07, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
November 02, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 31, 2023
Via
Benzinga
Onconova Expands Leadership Team with Two Key Appointments
October 24, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
October 19, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Encouraging Rigosertib Data Presented at EADV as Late Breaker
October 12, 2023
Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 11, 2023
Via
Benzinga
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
September 28, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
August 10, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
June 14, 2023
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
June 05, 2023
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.